Document is current

Article History

Accepted: 20 February 2025

First Online: 4 April 2025

Competing interests

: J.L.C. has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. B.K.F. is a full-time employee of The Michael J. Fox Foundation for Parkinson’s Research and has no conflicts of interest to disclose. I.L.B. has served on a Medical Advisory Board and has a consultancy agreement with Alector and Prevail Therapeutics/Lilly. C.E.T. performed contract research for Acumen, ADx Neurosciences, AC Immune, Alamar, Aribio, Axon Neurosciences, Beckman–Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vivoryon. C.E.T. is editor in chief of Alzheimer’s Research & Therapy, and serves on editorial boards of Medidact Neurologie/Springer, and Neurology: Neuroimmunology & Neuroinflammation, Alzheimer’s & Dementia and Molecular Neurodegeneration. K.R.W. is a full-time employee of Eisai. M.S. has served or serves on advisory boards for Arvakor, Eli Lilly, Novo Nordisk and Roche, has received speaker honoraria from Bioarctic, Genentech, Novo Nordisk, Eli Lilly, Roche and Triolabs and receives research support (paid to institution) from Alzpath, Beckman–Coulter, Bioarctic, Gates Ventures, Novo Nordisk and Roche. He is a co-founder and stakeholder of Centile Bioscience and serves as Associate Editor of Alzheimer’s Research & Therapy. B.D. has provided consultation to Prothena Biosciences. P.S. is a full-time employee of EQT Life Sciences (formerly LSP). He reports having received consultancy fees (paid to Vrije Universiteit Amsterdam) from AC Immune, Alzheon, BrainStorm Cell, FUJIFILM/Toyama, Green Valley and Novo Nordisk.